Chemotherapy Induced Diarrhea Epidemiology

Key Highlights

• Gastrointestinal side effects of chemotherapy are a debilitating and often overlooked clinical hurdle in cancer management. Diarrhea is a well-recognized side effect associated with various phases of a cancer patient’s treatment cycle. It is defined as the frequent passage of loose stools with urgency (or more frequent passage than is normal for the individual).
• Chemotherapy-induced diarrhea, also called chemotherapy-related diarrhea, is a common problem in cancer patients and is most often described with fluoropyrimidines, irinotecan, and several molecularly targeted agents.
• In 2022, the total incident cases of selected cancers were 3.2 million, which will rise up to 3.7 million at a CAGR of 1.1%. Among these, incident cases of breast, lung, colorectal, CRPC, and bladder cancer make up approximately 70% of all cases.
• Approximately 60% of these cancer incident cases receive chemotherapy. In the US, while the maximum chemotherapy usage has been seen in ovarian, stomach, and head and neck cancer, CRPC has been reported to have minimum chemotherapy usage.
• In 2022, the total incident cases of Chemotherapy-induced diarrhea were ~1 million in the 7MM, which might increase and reach ~1.2 million cases by 2034 at a CAGR of 1.2%.
• Lung cancer accounts for 25% of total Chemotherapy-induced Diarrhea cases. Moreover, lung, colorectal, breast, stomach, and bladder cancer alone contribute to 80% of all cases.

DelveInsight’s “Chemotherapy-induced Diarrhea (CID) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of the Chemotherapy-induced diarrhea, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Chemotherapy-induced Diarrhea Understanding and Diagnostic Algorithm

Chemotherapy-induced Diarrhea Overview

Most patients with cancer receive curative or palliative chemotherapeutic intervention throughout their treatment course. Gastrointestinal toxicities, including nausea, vomiting, ulceration, bleeding, constipation, and diarrhea, are often the major causes of treatment delays, dose adjustment, and treatment discontinuation during chemotherapy. Diarrhea is an unpleasant but common side effect in people receiving treatment for cancer, or cancer itself may cause it. The duration and severity of diarrhea may depend on the factors causing it; sometimes, it can signify something more serious. Diarrhea is a well-recognized side effect associated with various phases of a patient with cancer’s treatment cycle. It is defined as the frequent passage of loose stools with urgency (or more frequent passage than is normal for the individual). Objectively defined, it is the passage of more than three unformed stools in 24 h.

Chemotherapy-induced diarrhea (CID), also called chemotherapy-related diarrhea, can be associated with various chemotherapy agents but is most commonly described with fluoropyrimidines (particularly fluorouracil [FU] and capecitabine) and irinotecan. Diarrhea is the dose-limiting and major toxicity of regimens containing a fluoropyrimidine with irinotecan. However, in addition to conventional cytotoxic drugs, many molecularly targeted agents (including tyrosine kinase inhibitors [TKIs] and monoclonal antibodies) are also associated with Chemotherapy-induced diarrhea. Diarrhea affects chemotherapy’s benefits by reducing the dose or delaying the schedule and decreasing patients’ quality of life; it can even increase the life-threatening risk of dehydration. Despite the severity of Chemotherapy-induced diarrhea, it is often not recognized by clinicians and is poorly managed.

Chemotherapy-induced Diarrhea Diagnosis

The severity is often described using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) grades. Severity is determined by the number of stools per day or increased ostomy output compared with baseline, the need for hospitalization, and the effect on self-care activities. It is critical to ascertain the patient’s baseline bowel pattern when grading the severity of Chemotherapy-induced diarrhea.

Evaluation of the patient begins with a history to determine the severity according to the NCI CTCAE grades. The volume and duration of diarrhea should also be determined, and the history should include questions concerning foods or drugs that might play a contributory role (usually avoided in patients with Chemotherapy-induced diarrhea). Recent initiation of proton pump inhibitors, nonsteroidal anti-inflammatory agents, antibiotics, laxatives, and/or a stool softener (e.g., to prevent opioid-induced constipation) can all cause or contribute to diarrhea. Because mucosal injury caused by chemotherapy may lead to a temporary lactase deficiency, ingesting milk-containing foods may be an important trigger for diarrhea and should be specifically queried.

Further details related to diagnosis are provided in the report…

Chemotherapy-induced Diarrhea Epidemiology

The epidemiology forecast model of Chemotherapy-induced diarrhea for the 7MM is based on the analysis of the incident cases of selected cancer types (colorectal cancer, breast cancer, bladder cancer, cervical cancer, esophageal cancer, head and neck, lung cancer, ovarian cancer, pancreatic cancer, testicular cancer, stomach cancer, endometrial cancer, castration-resistant prostate cancer), which is further segmented by patients on chemotherapies by cancer type, incident cases of Chemotherapy-induced diarrhea, grade-specific cases.

As the market is derived using the patient-based model, the Chemotherapy-induced Diarrhea epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Incident Cases of Selected Cancer Types, Total Patients on Chemotherapies by Cancer Type, Incident Cases of Chemotherapy-induced Diarrhea by Selected Cancer Types, Grade-specific Incident Cases of Chemotherapy-induced Diarrhea, and Total Treated Cases of Chemotherapy-induced Diarrhea in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), United Kingdom, Japan from 2021 to 2034. The total incident cases of Chemotherapy-induced diarrhea in the 7MM comprised approximately 1,041,1300 cases in 2022 and are projected to increase during the forecasted period.

• The incidence cases of Chemotherapy-induced diarrhea associated with lung cancer in the United States was 97,374 in 2022.
• Lung cancer accounts for 25% of total Chemotherapy-induced Diarrhea cases. Moreover, lung, colorectal, breast, stomach, and bladder cancer alone contribute to 80% of all cases.
• In 2022, the total incident cases of Chemotherapy-induced diarrhea were ~358,500 cases in the United States, which might reach ~417,100 cases by 2034. Among these, approximately 40% of cases develop Grade =3 Chemotherapy-induced Diarrhea.
• In 2022, among the selected 13 major indications, breast cancer contributed the highest number of patients on chemotherapies with 178,634 cases, followed by lung cancer contributing the second highest number of patients on chemotherapies with 177,752 cases in EU4 and the UK.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts contacted for insights on Chemotherapy-induced diarrhea evolving treatment landscape, patient reliance on conventional therapies, patient’s therapy switching acceptability, drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Medical Oncologists, and Professors, and Others.

Delveinsight’s analysts connected with 30+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as MD Anderson Cancer Center, American Cancer Society, etc., were contacted.

Scope of the Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of Chemotherapy-induced diarrhea, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the country-wise epidemiology segments and forecasts, the future growth potential of diagnosis rate, and insights on disease progression have been provided.
• A detailed review of the Chemotherapy-induced Diarrhea epidemiology, detailed assumptions, and rationale behind our approach is included in the report.
• A detailed review of current challenges in establishing the diagnosis.

Chemotherapy-induced Diarrhea Report Insights

• Chemotherapy-induced Diarrhea Patient Population
• Patient Population by the Patient On Chemotherapies, Grade-Specific Cases, and Others
• Country-wise Epidemiology Distribution

Chemotherapy-induced Diarrhea Report Key Strengths

• Ten years Forecast
• The 7MM Coverage
• Chemotherapy-induced Diarrhea Epidemiology Segmentation
• Chemotherapy-induced Diarrhea Report Assessment
• Epidemiology Segmentation
• Current Diagnostic Practices

Key Questions

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Chemotherapy-induced Diarrhea? What will be the growth opportunities across the 7MM with respect to the patient population of Chemotherapy-induced Diarrhea?
• What is the historical and forecasted Chemotherapy-induced Diarrhea patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Why do only limited patients appear with symptoms? Why is the current year diagnosis rate not high?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the Chemotherapy-induced Diarrhea Market.
• To understand key opinion leaders’ perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.